Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones certainly are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antib
The fluoroquinolones really are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, found in 1962 by Lescher and colleagues. The earliest fluoroquinolones were often since they were the sole orally administered agents an alternative for handling serious infections as a result of gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones possess a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones posses important part in the treatment of community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in kids
Newer quinolones produce additional toxicities towards the heart that were not found in the older elements
Fluoroquinolones advantages:
Simplicity of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal discount in activity against gram-negative bacteria. Their expanded gram-positive activity is extremely important this is because includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing when compared to the newer quinolones, and they are more susceptible to the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications within the remedy for complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are classified as the preferred second-generation quinolones because of the availability in oral and intravenous formulations and the broad set of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated right into a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for instance Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they may be less active than ciprofloxacin against Pseudomonas species.
Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species corresponding to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Due to bother about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), as well as the drug is necessary for no more than 14 days.
Side effects
The fluoroquinolones to be a class some times well tolerated. Most negative effects are mild in severity, self-limited, and barely end in treatment discontinuation. However, they can have serious adverse reactions.
Fluoroquinolones are approved for use only in people older than 18. They could affect the increase of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating which these drugs have the possibility to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy is not recommended unless the positive aspects justify the new risks towards the fetus. These agents can also be excreted in breast milk and should be ignored during breast-feeding if possible.
Gastrointestinal effects. The commonest adverse effects acquainted with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have been reported to all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones ought to be avoided in patients by using a history of convulsion, cerebral trauma, or anoxia. No seizures are actually reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms for instance dizziness took place in about 50% of the patients.
Phototoxicity. Experience with ultraviolet A rays from direct or indirect sunlight really should be avoided during treatment and a number of other days (5 days with sparfloxacin) following the consumption of clonazepam. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Worry about the building of musculoskeletal effects, evident in animal studies, has led towards the contraindication of fluoroquinolones for routine use in children as well as in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within weeks time of discontinuation of therapy, spontaneous ruptures are actually reported so long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant by using corticosteroids.
Hepatoxicity. Trovafloxacin use is connected with rare liver damage, which prompted the withdrawal of the oral preparations out of your U.S. market. However, the IV preparation is still intended for treatment of infections so serious which the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have already been found to create additional toxicities into the heart which are not found with all the older compounds. Evidence advices that sparfloxacin and grepafloxacin could possibly have the foremost cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia seem to have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia continues to be reported with other fluoroquinolones (levofloxacin and moxifloxacin), the consequences are actually mild.
Hypersensitivity. Hypersensitivity reactions occur very rarely during quinolone therapy and are generally mild to moderate in severity, and often resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important role in managing community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of a typical fluoroquinolones vary from 3 -20 hours, letting a couple of times daily dosing.
Author Resource:-
The fluoroquinolones really are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of your group is nalidixic acid, taken from 1962 by Lescher and colleagues. The earliest fluoroquinolones were often since they were the only real orally administered agents intended for treating serious infections attributable to gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important part in treating community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in youngsters
Newer quinolones produce additional toxicities to your heart which were not found in the older constituents
Fluoroquinolones advantages:
No-fuss administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
To be a group, the fluoroquinolones have excellent in vitro activity against a wide variety of both gram-positive and gram-negative bacteria. The latest fluoroquinolones have enhanced activity against gram-positive bacteria with just the lowest decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is extremely important because it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, understanding the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing when compared to the newer quinolones, and are also more susceptible to your development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, in addition to some gram-positive and atypical pathogen coverage. In comparison to first-generation quinolones, these drugs have broader clinical applications inside the remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will probably be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are classified as the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and also their broad pair of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated inside third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, these are less active than ciprofloxacin against Pseudomonas species.
Because of the expanded antimicrobial spectrum, third-generation fluoroquinolones are of help in the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. Additionally they retain activity against Pseudomonas species corresponding to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
On account of bother about hepatotoxicity, trovafloxacin therapy really should be available to life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and also the drug is necessary for no more than 14 days.
Side effects
The fluoroquinolones to be a class some times well tolerated. Most adverse reactions are mild in severity, self-limited, and occasionally end in treatment discontinuation. However, they will be able to have serious adverse effects.
Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the development of bones, teeth, and cartilage inside of a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating which these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will never be recommended unless the positive aspects justify inpending risks to the fetus. These agents may also be excreted in breast milk and may even be ignored during breast-feeding if possible.
Gastrointestinal effects. A typical adverse effects informed about fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in a single to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have already been reported to all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients that has a tradition of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With all the older non-fluorinated quinolones neurotoxic symptoms for example dizziness happened in about 50% of the patients.
Phototoxicity. Experience with ultraviolet A rays from direct or indirect sunlight ought to be avoided during treatment and several other days (5 days with sparfloxacin) when by using the medication. The degree of phototoxic potential of fluoroquinolones can be as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Be worried about the introduction of musculoskeletal effects, evident in animal studies, has led to your contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 7 days of discontinuation of therapy, spontaneous ruptures are actually reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant consumption of corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be linked to rare liver damage, which prompted the withdrawal of many oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious the fact that benefits outweigh the risks.
Cardiovascular effects. The newer quinolones seem to have been found to create additional toxicities into the heart which are not found in the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia are actually reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the consequences seem to have been mild.
Hypersensitivity. Hypersensitivity reactions occur very rarely during quinolone therapy and can be mild to moderate in severity, and often resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important function in managing community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones diverge from 3 -20 hours, providing once or twice daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites